Shionogi's Xocova Extends Global Reach Through First MPP Sublicenses

The first sublicensing deals through MPP for Shionogi's oral COVID antiviral Xocova with seven firms in China, India, Ukraine and Vietnam suggest the global debut of generic versions will come earlier than usual after the original, which continues in multiple global Phase III programs in various settings. While sales hopes are high, the drug may also be hit by a price cut in its first and biggest market so far – Japan.  

Xocova's sublicensing deal suggests its global debut may come earlier than the original product.
Xocova's sublicensing deal to provide drug in 117 low- and-middle-income countries. • Source: Shutterstock

The first sublicensing agreements for Shionogi & Co. Ltd.’s Xocova (ensitrelvir; S-217622) have been reached following the Japanese firm's alliance with the Medicines Patent Pool (MPP) last year. Deals have now been signed for the oral COVID-19 antiviral with seven generic firms in China, India, Ukraine and Vietnam.

If they successfully proceed, the arrangement means that officially licensed generic versions can be launched earlier than usual after the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip